Central nervous system effects of moxonidine experimental sustained release formulation in patients with mild to moderate essential hypertension

British Journal of Clinical Pharmacology

Volumn 55, Issue 6, 2003, Pages 518-525

  Kemme, Michiel J B ^a   Post, Jeroen P V D ^a   Schoemaker, Rik C ^a   Straub, Matthias ^b   Cohen, Adam F ^a   Van Gerven, Joop M A ^a  

^a CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

^b Solvay Pharmaceuticals Inc   (Netherlands)

Author keywords

Centrally acting antihypertensive; Hypertensive patients; Saccadic eye movements; Tolerance

Indexed keywords

MOXONIDINE; PLACEBO;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG FORMULATION; DRUG TOLERANCE; ELECTROENCEPHALOGRAM; FEMALE; HUMAN; HYPERTENSION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SLEEP DEPRIVATION; SUSTAINED RELEASE PREPARATION; VISUAL ANALOG SCALE;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DELAYED-ACTION PREPARATIONS; DRUG TOLERANCE; ELECTROENCEPHALOGRAPHY; FEMALE; HEART RATE; HUMANS; HYPERTENSION; IMIDAZOLES; MALE; MIDDLE AGED; SACCADES;

EID: 0037789577     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01796.x     Document Type: Article

References (16)

1. Ernsberger P, Damon TH, Graft LM, Schafer SG, Christen MO. Moxonidine, a centrally acting antihypertensive agent, is a selective ligand for I1-imidazoline sites. J Pharmacol Exp Ther 1993; 264: 172-182.
2. Van Zwieten PA. The renaissance of centrally acting antihypertensive drugs. J Hypertens 1999; 17 (Suppl 3): S15-S21.
3. Prichard BN, Graham BR, Owens CW. Moxonidine: a new antiadrenergic antihypertensive agent. J Hypertens 1999; 17 (Suppl 3): S41-S54.
4. Macphee GJ, Howie CA, Elliott HL, Reid JL. A comparison of the haemodynamic and behaviourai effects of moxonidine and clonidine in normotensive subjects. Br J Clin Pharmacol 1992; 33: 261-267.
5. Planitz V. Crossover comparison of moxonidine and clonidine in mild to moderate hypertension. Eur J Clin Pharmacol 1984; 27: 147-152.
6. Schachter M. Moxonidine: a review of safety and tolerability after seven years of clinical experience. J Hypertens 1999; 17 (Suppl 3): S37-S39.
7. van Steveninck AL, Mandema JW, Tuk B et al. A comparison of the concentration - effect relationships of midazolam for EEG-derived parameters and saccadic peak velocity. Br J Clin Pharmacol 1993; 36: 109-115.
8. van Steveninck AL, Wallnofer AE, Schoemaker RC et al. A study of the effects of long-term use on individual sensitivity to temazepam and lorazepam in a clinical population. Br J Clin Pharmacol 1997; 44: 267-275.
9. Harron DW, Hasson B, Regan M, McClelland RJ, King DJ. Effects of rilmenidine and clonidine on the electroencephalogram, saccadic eye movements, and psychomotor function. J Cardiovasc Pharmacol 1995; 26 (Suppl 2): S48-S54.
10. van Steveninck AL, van Berckel BN, Schoemaker RC, Breimer DD, van Gerven JM, Cohen AF. The sensitivity of pharmacodynamic tests for the central nervous system effects of drugs on the effects of sleep deprivation. J Psychopharmacol 1999; 13: 10-17.
11. Bond AJ, Lader MH. The use of analogue scales in rating subjective feelings. Br J Med Psychol 1974; 47: 211-218.
12. Norris H. The action of sedatives on brain stem oculomotor systems in man. Neuropharmacology 1971; 10: 181-191.
13. Schoemaker HC, Cohen AF. Estimating impossible curves using NONMEM. Br J Clin Pharmacol 1996; 42: 283-290.
14. Santamaria J, Chiappa KH. The EEG of drowsiness in normal adults. J Clin Neurophysiol 1995; 4: 327-382.
15. Geyskes GG, Boer P, Dorhout Mees EJ. Clonidine withdrawal. Mechanism and frequency of rebound hypertension. Br J Clin Pharmacol 1979; 7: 55-62.
16. Webster J, Koch HF. Aspects of tolerability of centrally acting antihypertensive drugs. J Cardiovasc Pharmacol 1996; 27 (Suppl 3): S49-S54.